194 related articles for article (PubMed ID: 17134614)
1. Phase I and Phase II enzyme polymorphisms and childhood cancer.
Swinney R; Hsu S; Tomlinson G
J Investig Med; 2006 Sep; 54(6):303-20. PubMed ID: 17134614
[TBL] [Abstract][Full Text] [Related]
2. [Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes].
Ozawa S
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):69-81. PubMed ID: 10097514
[TBL] [Abstract][Full Text] [Related]
3. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
Nebert DW; McKinnon RA; Puga A
DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
[TBL] [Abstract][Full Text] [Related]
4. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
[TBL] [Abstract][Full Text] [Related]
5. The role of individual susceptibility in cancer burden related to environmental exposure.
Bartsch H; Hietanen E
Environ Health Perspect; 1996 May; 104 Suppl 3(Suppl 3):569-77. PubMed ID: 8781385
[TBL] [Abstract][Full Text] [Related]
6. Phenotype prediction of nonsynonymous single nucleotide polymorphisms in human phase II drug/xenobiotic metabolizing enzymes: perspectives on molecular evolution.
Hao D; Xiao P; Chen S
Sci China Life Sci; 2010 Oct; 53(10):1252-62. PubMed ID: 20953949
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of drug-metabolizing enzymes and risk of childhood acute lymphoblastic leukemia.
Pakakasama S; Mukda E; Sasanakul W; Kadegasem P; Udomsubpayakul U; Thithapandha A; Hongeng S
Am J Hematol; 2005 Jul; 79(3):202-5. PubMed ID: 15981231
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia.
Krajinovic M; Labuda D; Mathonnet G; Labuda M; Moghrabi A; Champagne J; Sinnett D
Clin Cancer Res; 2002 Mar; 8(3):802-10. PubMed ID: 11895912
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of drug-metabolizing enzymes in Italian populations.
Serpe L; Canaparo R; Scordo MG; Spina E
Drug Metab Pers Ther; 2015 Jun; 30(2):107-20. PubMed ID: 25527811
[TBL] [Abstract][Full Text] [Related]
10. Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo.
Chattopadhyay M; Kodela R; Nath N; Street CR; Velázquez-Martínez CA; Boring D; Kashfi K
Biochem Pharmacol; 2012 Mar; 83(6):733-40. PubMed ID: 22209714
[TBL] [Abstract][Full Text] [Related]
11. [Study on polymorphisms in metabolic enzyme genes, DNA repair genes and individual susceptibility to childhood leukemia].
Zhu R; Xia Z
Wei Sheng Yan Jiu; 2004 Sep; 33(5):635-8. PubMed ID: 15612500
[TBL] [Abstract][Full Text] [Related]
12. Childhood acute lymphoblastic leukemia: genetic determinants of susceptibility and disease outcome.
Krajinovic M; Labuda D; Sinnett D
Rev Environ Health; 2001; 16(4):263-79. PubMed ID: 12041882
[TBL] [Abstract][Full Text] [Related]
13. Review of studies of selected metabolic polymorphisms and cancer.
d'Errico A; Malats N; Vineis P; Boffetta P
IARC Sci Publ; 1999; (148):323-93. PubMed ID: 10493265
[No Abstract] [Full Text] [Related]
14. Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome.
Chacko P; Joseph T; Mathew BS; Rajan B; Pillai MR
Mutat Res; 2005 Mar; 581(1-2):153-63. PubMed ID: 15725614
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility--a review.
Raunio H; Husgafvel-Pursiainen K; Anttila S; Hietanen E; Hirvonen A; Pelkonen O
Gene; 1995 Jun; 159(1):113-21. PubMed ID: 7607565
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia.
Canalle R; Burim RV; Tone LG; Takahashi CS
Environ Mol Mutagen; 2004; 43(2):100-9. PubMed ID: 14991750
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes.
Voso MT; Fabiani E; D'Alo' F; Guidi F; Di Ruscio A; Sica S; Pagano L; Greco M; Hohaus S; Leone G
Ann Oncol; 2007 Sep; 18(9):1523-8. PubMed ID: 17761709
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphism and their contribution to cancer susceptibility.
Conforti-Froes N; el-Zein R; Au W
Cad Saude Publica; 1998; 14 Suppl 3():7-13. PubMed ID: 9819460
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.
MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
Breast Cancer Res Treat; 2010 Jan; 119(2):463-74. PubMed ID: 19424794
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification.
Iyanagi T
Int Rev Cytol; 2007; 260():35-112. PubMed ID: 17482904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
